Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Immunity-related GTPase Q (IRGQ) is a member of the IRG family of interferon-inducible, dynamin-like large GTPases critical for cell-autonomous defense against intracellular pathogens. IRG proteins are rapidly induced by interferon-gamma (IFNγ) and localize to pathogen-containing vacuoles within cells, promoting the rupture of these compartments and exposing pathogens to cytosolic immune effectors. About 20 effector IRGs—including IRGQ—are regulated by three membrane-bound IRG family members and recognize specific membrane signals, leading to targeted elimination of intracellular bacteria and protozoa such as *Toxoplasma gondii* and *Chlamydia trachomatis*. IRGQ itself functions as part of a coordinated defense network, with its activity linked to GTP binding and hydrolysis, membrane targeting, and the disruption of pathogen-containing vacuoles. While IRGs are not currently targeted by drugs, their central role in antimicrobial immunity makes them an area of interest for research into resistance and immune system modulation[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Immunity-related GTPase Q (IRGQ).